Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
NCT ID: NCT02709746
Last Updated: 2020-08-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
784 participants
INTERVENTIONAL
2016-05-31
2019-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
NCT02709655
Vortioxetine to Prevent Return of Symptoms in Children With Depression
NCT05014919
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
NCT02919501
Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
NCT02371980
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
NCT00811252
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vortioxetine 10 mg/day
Vortioxetine 10 mg/day
10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Vortioxetine 20 mg/day
Vortioxetine 20 mg/day
20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Fluoxetine 20 mg/day,
Fluoxetine 20 mg/day
20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Placebo
Placebo
Encapsulated tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vortioxetine 10 mg/day
10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Vortioxetine 20 mg/day
20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Fluoxetine 20 mg/day
20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Placebo
Encapsulated tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient has Major depressive disorder (MDD), diagnosed according to DSM-5™.
* The patient has a Children Depression Rating Scale - Revised (CDRS-R) total score ≥45 at the Screening Visit and at the Baseline.
* The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≥4 at the Screening Visit and at the Baseline
* The patient has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.
Exclusion Criteria
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
H. Lundbeck A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
US1369
Dothan, Alabama, United States
US1333
Tucson, Arizona, United States
US1310
Little Rock, Arkansas, United States
US1062
Costa Mesa, California, United States
US1387
Downey, California, United States
US1114
Escondido, California, United States
US1118
Glendale, California, United States
US1123
Imperial, California, United States
US1160 Renew Behavioral Health, Inc.
Long Beach, California, United States
US1368
Orange, California, United States
US1370
Panorama City, California, United States
US1351
Wildomar, California, United States
US1133
Washington D.C., District of Columbia, United States
US1217
Gainesville, Florida, United States
US1229
Orange City, Florida, United States
US1009
Atlanta, Georgia, United States
US1313
Marietta, Georgia, United States
US1311
Naperville, Illinois, United States
US1315
Naperville, Illinois, United States
US1103
Oak Brook, Illinois, United States
US1386
Wichita, Kansas, United States
US1261
Lake Charles, Louisiana, United States
US1015
Baltimore, Maryland, United States
US1385 Ericksen Research And Development
Clinton, Mississippi, United States
US1064
Creve Coeur, Missouri, United States
US1314
O'Fallon, Missouri, United States
US1266
Saint Charles, Missouri, United States
US1312
Berlin, New Jersey, United States
US1222
Princeton, New Jersey, United States
US1317
New York, New York, United States
US1171
Rochester, New York, United States
US1190
Staten Island, New York, United States
US1051
Cincinnati, Ohio, United States
US1054
Cleveland, Ohio, United States
US1334
Middleburg Heights, Ohio, United States
US1323
Oklahoma City, Oklahoma, United States
US1329
Oklahoma City, Oklahoma, United States
US1328
Austin, Texas, United States
US1320
Plano, Texas, United States
US1162
San Antonio, Texas, United States
US1308
Orem, Utah, United States
US1309
Richmond, Virginia, United States
BG1023
Targovishte, , Bulgaria
BG1025
Varna, , Bulgaria
CA1036 University of Calgary
Calgary, , Canada
CA1038
Toronto, , Canada
CO1003
Barranquilla, , Colombia
CO1001
Bello, , Colombia
CO1004
Bogotá, , Colombia
CO1002
Pereira, , Colombia
EE1007
Tallinn, , Estonia
EE1015
Viljandi, , Estonia
FR1041
Douai, , France
FR1017
Élancourt, , France
FR1009
Nantes, , France
DE1078
Freiburg im Breisgau, , Germany
DE1034
Mainz, , Germany
DE1077
Mannheim, , Germany
DE1081
Maulbronn, , Germany
DE1076
Tübingen, , Germany
HU1023
Budapest, , Hungary
HU1020
Gyula, , Hungary
IT1075
Cagliari, , Italy
IT1073
Genova, , Italy
IT1029
Messina, , Italy
IT1068
Napoli, , Italy
IT1074
Padua, , Italy
IT1070
Pisa, , Italy
IT1072 Osppedale Bambin gesu
Rome, , Italy
LV1002
Jelgava, , Latvia
LV1008
Liepāja, , Latvia
LV1009
Riga, , Latvia
LV1007
Sigulda, , Latvia
MX1014
Culiacán, , Mexico
MX1011
Guadalajara, , Mexico
MX1013
Guadalajara, , Mexico
MX1022
Guadalajara, , Mexico
MX1023
Mazatlán, , Mexico
MX1003
Mexico City, , Mexico
MX1001
Nuevo León, , Mexico
PL1002
Bialystok, , Poland
PL1050
Gdansk, , Poland
PL1068
Kielce, , Poland
PL1057
Lublin, , Poland
PL1052
Poznan, , Poland
PL1054
Wąbrzeźno, , Poland
PL1051
Wroclaw, , Poland
RU1009
Arkhangelsk, , Russia
RU1059
Engel's, , Russia
RU1046
Krasnodar, , Russia
RU1011
Lipetsk, , Russia
RU1004
Nizhny Novgorod, , Russia
RU1010
Novosibirsk, , Russia
RU1012
Rostov-on-Don, , Russia
RU1044
Rostov-on-Don, , Russia
RU1030
Saint Petersburg, , Russia
RU1013
Saratov, , Russia
RU1038
Saratov, , Russia
RU1057
Tomsk, , Russia
RU1048
Tonnel'nyy, , Russia
RU1016
Yekaterinburg, , Russia
RS1006 Clinic of Neurology and Psychiatry for Children and Adolescents
Belgrade, , Serbia
RS1010
Belgrade, , Serbia
RS1011
Kragujevac, , Serbia
RS1003
Niš, , Serbia
RS1007
Novi Sad, , Serbia
ZA1019
Cape Town, , South Africa
ZA1022
Randburg, , South Africa
ZA1023
Sandton, , South Africa
KR1035
Cheonan, , South Korea
UA1037
Gyeongsang, , South Korea
KR1032
Seoul, , South Korea
KR1038
Seoul, , South Korea
ES1041
Alcorcón, , Spain
ES1044
Madrid, , Spain
ES1043
Pamplona, , Spain
ES1018 Hospital de Sabadell
Sabadell, , Spain
ES1040
Torremolinos, , Spain
UA1002
Kyiv, , Ukraine
UA1019
Odesa, , Ukraine
UA1001
Poltava, , Ukraine
UA1004
Ternopil, , Ukraine
GB1051
Glasgow, , United Kingdom
GB1047
Liverpool, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Findling RL, DelBello MP, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. J Am Acad Child Adolesc Psychiatry. 2022 Sep;61(9):1106-1118.e2. doi: 10.1016/j.jaac.2022.01.004. Epub 2022 Jan 13.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-005354-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
12710A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.